Nurix Therapeutics, Inc.
NRIXNasdaqCIK 1549595HealthcareFiscal year ends Nov 30
Reports and events: 115 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-02-1516:04 ET | 10-K | Annual reportPeriod 2023-11-30 | 0001549595-24-000025 |
| 2024-02-1516:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001549595-24-000024 |
| 2024-01-0807:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001549595-24-000003 |
| 2023-12-1112:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001549595-23-000062 |
| 2023-11-1307:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-275300 |
| 2023-11-0116:02 ET | 8-K | 8.01 Other events | 0001549595-23-000053 |
| 2023-10-1216:06 ET | 10-Q | Quarterly reportPeriod 2023-08-31 | 0001549595-23-000048 |
| 2023-10-1216:03 ET | 8-K | 2.02 Results of operations | 0001549595-23-000046 |
| 2023-09-0707:02 ET | 8-K | 1.01 Entry into a material agreement | 0001549595-23-000042 |
| 2023-07-1316:19 ET | 10-Q | Quarterly reportPeriod 2023-05-31 | 0001549595-23-000040 |
| 2023-07-1316:18 ET | 8-K | 2.02 Results of operations | 0001549595-23-000039 |
| 2023-05-0416:09 ET | 8-K | 5.07 Shareholder vote results | 0001549595-23-000034 |
| 2023-04-1316:04 ET | 10-Q | Quarterly reportPeriod 2023-02-28 | 0001549595-23-000032 |
| 2023-04-1316:02 ET | 8-K | 2.02 Results of operations | 0001549595-23-000030 |
| 2023-04-1007:16 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-095819 |
| 2023-03-2407:00 ET | DEF 14A | Proxy statementPeriod 2023-05-04 | 0001140361-23-013573 |
| 2023-03-1317:26 ET | 8-K | 8.01 Other events | 0001193125-23-069218 |
| 2023-02-0916:19 ET | 10-K | Annual reportPeriod 2022-11-30 | 0001549595-23-000021 |
| 2023-02-0916:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001549595-23-000020 |
| 2023-01-0907:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-004115 |
| 2022-12-1616:07 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-22-307328 |
| 2022-12-1317:36 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-302915 |
| 2022-10-2607:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-269014 |
| 2022-10-0616:28 ET | 10-Q | Quarterly reportPeriod 2022-08-31 | 0001564590-22-033709 |
| 2022-10-0616:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-22-033701 |
| 2022-09-1416:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-22-244711 |
| 2022-07-0816:13 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-190492 |
| 2022-07-0716:17 ET | 10-Q | Quarterly reportPeriod 2022-05-31 | 0001564590-22-025450 |
| 2022-07-0716:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-22-025443 |
| 2022-05-2607:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-160275 |
| 2022-05-1606:08 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-150768 |
| 2022-05-0607:00 ET | 8-K | 5.07 Shareholder vote results | 0001193125-22-142944 |
| 2022-04-0816:07 ET | 10-Q | Quarterly reportPeriod 2022-02-28 | 0001564590-22-013988 |
| 2022-04-0716:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-22-013841 |
| 2022-03-2507:01 ET | DEF 14A | Proxy statementPeriod 2022-05-05 | 0001193125-22-084520 |
| 2022-03-0716:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-067928 |
| 2022-03-0216:07 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-22-062963 |
| 2022-01-2816:11 ET | 10-K | Annual reportPeriod 2021-11-30 | 0001564590-22-003007 |
| 2022-01-2716:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-22-002664 |
| 2022-01-1007:11 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-005046 |
| 2021-10-2707:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-21-308663 |
| 2021-10-1417:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-050869 |
| 2021-10-1416:20 ET | 10-Q | Quarterly reportPeriod 2021-08-31 | 0001564590-21-050851 |
| 2021-09-3007:08 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-21-287318 |
| 2021-07-1316:18 ET | 10-Q | Quarterly reportPeriod 2021-05-31 | 0001564590-21-036448 |
| 2021-07-1316:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-036443 |
| 2021-07-0916:27 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-21-211877 |
| 2021-06-2116:17 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-195077 |
| 2021-06-0207:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-21-179209 |
| 2021-06-0116:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-21-178533 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.